NR_NARPS
ID NR_NARPS Reviewed; 257 AA.
AC A0A1A9TAK5; A0A1A9TAK3; A0A2H5AIZ2;
DT 12-AUG-2020, integrated into UniProtKB/Swiss-Prot.
DT 05-OCT-2016, sequence version 1.
DT 03-AUG-2022, entry version 19.
DE RecName: Full=Noroxomaritidine/norcraugsodine reductase {ECO:0000303|PubMed:27252378, ECO:0000303|PubMed:29229969};
DE Short=NorRed {ECO:0000303|PubMed:29229969};
DE EC=1.1.1.- {ECO:0000269|PubMed:27252378};
GN Name=NR {ECO:0000303|PubMed:27252378, ECO:0000303|PubMed:29229969};
OS Narcissus pseudonarcissus (Daffodil).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Amaryllidaceae;
OC Amaryllidoideae; Narcissus.
OX NCBI_TaxID=39639;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], REVIEW ON THE AMARYLLIDACEAE ALKALOID
RP METABOLISM, PATHWAY, TISSUE SPECIFICITY, GENE FAMILY, AND NOMENCLATURE.
RC STRAIN=cv. King Alfred; TISSUE=Bulb;
RX PubMed=29229969; DOI=10.1038/s41598-017-17724-0;
RA Singh A., Desgagne-Penix I.;
RT "Transcriptome and metabolome profiling of Narcissus pseudonarcissus 'King
RT Alfred' reveal components of Amaryllidaceae alkaloid metabolism.";
RL Sci. Rep. 7:17356-17356(2017).
RN [2]
RP X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) IN COMPLEX WITH NADP AND SUBTRATE,
RP FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX PubMed=27252378; DOI=10.1074/jbc.m116.717827;
RA Kilgore M.B., Holland C.K., Jez J.M., Kutchan T.M.;
RT "Identification of a noroxomaritidine reductase with amaryllidaceae
RT alkaloid biosynthesis related activities.";
RL J. Biol. Chem. 291:16740-16752(2016).
CC -!- FUNCTION: In the Amaryllidaceae alkaloids biosynthesic pathway,
CC catalyzes the conversion of noroxomaritidine to oxomaritidine, a
CC precursor of haemanthamine- and crinamine-type alkaloids, promising
CC anticancer agents (PubMed:27252378). Can also, to some extent, catalyze
CC the condensation of 3,4-dihydroxybenzaldehyde (3,4-DHBA) and tyramine
CC to produce norbelladine, and of isovanillin and tyramine to produce 4'-
CC O-methylnorbelladine (PubMed:27252378). {ECO:0000269|PubMed:27252378}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=(10bR,4aS)-noroxomaritidine + H(+) + NADPH = (10bR,4aS)-
CC oxomaritidine + NADP(+); Xref=Rhea:RHEA:63196, ChEBI:CHEBI:15378,
CC ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:133995,
CC ChEBI:CHEBI:146208; Evidence={ECO:0000269|PubMed:27252378};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63197;
CC Evidence={ECO:0000269|PubMed:27252378};
CC -!- CATALYTIC ACTIVITY:
CC Reaction=(10bS,4aR)-noroxomaritidine + H(+) + NADPH = (10bS,4aR)-
CC oxomaritidine + NADP(+); Xref=Rhea:RHEA:63200, ChEBI:CHEBI:15378,
CC ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:133996,
CC ChEBI:CHEBI:146209; Evidence={ECO:0000269|PubMed:27252378};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63201;
CC Evidence={ECO:0000269|PubMed:27252378};
CC -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC pH dependence:
CC Optimum pH is 6. {ECO:0000269|PubMed:27252378};
CC Temperature dependence:
CC Optimum temperature is 35 degrees Celsius.
CC {ECO:0000269|PubMed:27252378};
CC -!- PATHWAY: Alkaloid biosynthesis. {ECO:0000269|PubMed:27252378,
CC ECO:0000303|PubMed:29229969}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=A0A1A9TAK5-1; Sequence=Displayed;
CC Name=2;
CC IsoId=A0A1A9TAK5-2; Sequence=VSP_060653;
CC -!- TISSUE SPECIFICITY: Mostly expressed in stems, and, to a lower extent,
CC in bulbs, roots and flowers. {ECO:0000269|PubMed:29229969}.
CC -!- SIMILARITY: Belongs to the short-chain dehydrogenases/reductases (SDR)
CC family. SDR65C subfamily. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; MF416099; AUG71944.1; -; mRNA.
DR PDB; 5FEU; X-ray; 1.73 A; A=1-257.
DR PDB; 5FF9; X-ray; 1.81 A; A/B/C/D=1-257.
DR PDB; 5FFF; X-ray; 1.50 A; A/B=1-257.
DR PDBsum; 5FEU; -.
DR PDBsum; 5FF9; -.
DR PDBsum; 5FFF; -.
DR AlphaFoldDB; A0A1A9TAK5; -.
DR SMR; A0A1A9TAK5; -.
DR GO; GO:0000166; F:nucleotide binding; IEA:UniProtKB-KW.
DR GO; GO:0016491; F:oxidoreductase activity; IEA:UniProtKB-KW.
DR GO; GO:0009820; P:alkaloid metabolic process; IEA:UniProtKB-KW.
DR InterPro; IPR036291; NAD(P)-bd_dom_sf.
DR InterPro; IPR020904; Sc_DH/Rdtase_CS.
DR InterPro; IPR002347; SDR_fam.
DR InterPro; IPR045000; TR.
DR PANTHER; PTHR42898; PTHR42898; 1.
DR PRINTS; PR00081; GDHRDH.
DR PRINTS; PR00080; SDRFAMILY.
DR SUPFAM; SSF51735; SSF51735; 1.
DR PROSITE; PS00061; ADH_SHORT; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Alkaloid metabolism; Alternative splicing; NADP;
KW Nucleotide-binding; Oxidoreductase.
FT CHAIN 1..257
FT /note="Noroxomaritidine/norcraugsodine reductase"
FT /id="PRO_0000450651"
FT ACT_SITE 161
FT /note="Proton acceptor"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU10001"
FT BINDING 20..23
FT /ligand="NADP(+)"
FT /ligand_id="ChEBI:CHEBI:58349"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FEU, ECO:0007744|PDB:5FF9,
FT ECO:0007744|PDB:5FFF"
FT BINDING 42..43
FT /ligand="NADP(+)"
FT /ligand_id="ChEBI:CHEBI:58349"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FEU, ECO:0007744|PDB:5FF9,
FT ECO:0007744|PDB:5FFF"
FT BINDING 68..69
FT /ligand="NADP(+)"
FT /ligand_id="ChEBI:CHEBI:58349"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FEU, ECO:0007744|PDB:5FF9,
FT ECO:0007744|PDB:5FFF"
FT BINDING 96..98
FT /ligand="NADP(+)"
FT /ligand_id="ChEBI:CHEBI:58349"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FEU, ECO:0007744|PDB:5FF9,
FT ECO:0007744|PDB:5FFF"
FT BINDING 100
FT /ligand="substrate"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FF9"
FT BINDING 149
FT /ligand="substrate"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FF9"
FT BINDING 161
FT /ligand="NADP(+)"
FT /ligand_id="ChEBI:CHEBI:58349"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FEU, ECO:0007744|PDB:5FF9,
FT ECO:0007744|PDB:5FFF"
FT BINDING 165
FT /ligand="NADP(+)"
FT /ligand_id="ChEBI:CHEBI:58349"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FEU, ECO:0007744|PDB:5FF9,
FT ECO:0007744|PDB:5FFF"
FT BINDING 194..199
FT /ligand="NADP(+)"
FT /ligand_id="ChEBI:CHEBI:58349"
FT /evidence="ECO:0000269|PubMed:27252378,
FT ECO:0007744|PDB:5FEU, ECO:0007744|PDB:5FF9,
FT ECO:0007744|PDB:5FFF"
FT VAR_SEQ 1
FT /note="M -> MASMTGGQQMGRGSM (in isoform 2)"
FT /id="VSP_060653"
FT CONFLICT 25
FT /note="H -> R (in Ref. 1; AUG71944)"
FT /evidence="ECO:0000305"
FT CONFLICT 81
FT /note="E -> D (in Ref. 1; AUG71944)"
FT /evidence="ECO:0000305"
FT CONFLICT 149
FT /note="C -> S (in Ref. 1; AUG71944)"
FT /evidence="ECO:0000305"
FT CONFLICT 201..204
FT /note="SFVI -> PFVN (in Ref. 1; AUG71944)"
FT /evidence="ECO:0000305"
FT CONFLICT 218
FT /note="F -> S (in Ref. 1; AUG71944)"
FT /evidence="ECO:0000305"
FT CONFLICT 254
FT /note="T -> A (in Ref. 1; AUG71944)"
FT /evidence="ECO:0000305"
FT HELIX 3..6
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 13..18
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 22..33
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 37..43
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 45..57
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 62..66
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 72..85
FT /evidence="ECO:0007829|PDB:5FFF"
FT TURN 86..88
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 91..95
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 105..107
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 110..120
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 122..137
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 139..146
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 149..151
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 152..154
FT /evidence="ECO:0007829|PDB:5FF9"
FT HELIX 159..178
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 180..182
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 184..191
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 197..199
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 200..204
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 206..213
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 224..235
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 237..239
FT /evidence="ECO:0007829|PDB:5FFF"
FT STRAND 246..250
FT /evidence="ECO:0007829|PDB:5FFF"
FT HELIX 253..255
FT /evidence="ECO:0007829|PDB:5FFF"
SQ SEQUENCE 257 AA; 27605 MW; 109567013CC857F8 CRC64;
MSLEKRWSLE GTTALVTGGT KGIGHAIVEE LVGFGARVYT CSRNEAELRK CLQEWENLKY
DVTGSVCDVS SRTEREKLAE EVSSVFNGKL NILINNAGGY VNKPIDGFTA EDFSFLVAVN
LESAFHLCQL AHPMLKASGT GSIVHISSCC AQIAIPGHSI YSSTKGAINQ LTRNLACEWA
KDNIRTNSIA PGAIRTPGTE SFVIDKDALD REVSRVPFGR IGEPEEVASL AAFLCMPSAS
YITGQVICVD GGRTING
